MediWound, an Israeli developer of products to treat burns and wounds using non-surgical tissue repair, said on Wednesday it ...

MediWound has commenced a pivotal, multicentre Phase III VALUE trial to assess its bioactive debridement therapy, EscharEx, ...

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure ...

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure Interim analysis planned after 65% of patients complete treatment, expected in ...

Recent health news covers various topics: a new mpox case in New York, promising results of Ozempic for alcohol use disorder, U.S. impact on global health funding, Robert F. Kennedy Jr.'s health ...

YAVNE, Israel - MediWound Ltd. (NASDAQ:MDWD), a biopharmaceutical company specializing in enzymatic therapies for tissue repair, has launched a Phase III clinical trial for its product EscharEx®, ...

YAVNE, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Chief Executive ...

YAVNE, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Chief Executive ...

(MENAFN- GlobeNewsWire - Nasdaq) YAVNE, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair ...

Given the large stake in the stock by institutions, MediWound's stock price might be vulnerable to their trading decisions 50% of the business is held by the top 8 shareholders Ownership research ...

Short MDWD slightly under 21.14, target 18.58, stop loss @ 21.2 Check the time stamp on this data. Updated AI-Generated Signals for Mediwound Ltd. (MDWD) available here: MDWD. Type a few symbols and ...